1,134 results match your criteria: "Italy C.H.; Clinica Sant'Anna[Affiliation]"
Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis.
Neurology
September 2024
From the Faculty of Medicine and Health (M.J.L., D.M.L., B.C.P.L., J.D.C., P.S.S.), and Centre for Healthy Brain Aging (CHeBA) (M.J.L., D.M.L., B.C.P.L., J.D.C., P.S.S.), Discipline of Psychiatry & Mental Health, School of Clinical Medicine, University of New South Wales, Sydney; School of Psychology and Public Health (B.C.P.L.), La Trobe University, Melbourne; The George Institute for Global Health (A.E.S., R.P.), Barangaroo; School of Biomedical Sciences (R.P.), University of New South Wales, Sydney, Australia; School of Public Health (R.P.), Imperial College London, United Kingdom; School of Population Health (A.E.S.), University of New South Wales, Sydney, Australia; Neuropsychiatric Epidemiology Unit (T.R.-S., J.N., I.S.), Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy, Centre for Ageing and Health (AGECAP) at the University of Gothenburg; Aging Research Center (T.R.-S.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University; Region Västra Götaland (J.N., I.S.), Sahlgrenska University Hospital, Psychiatry, Cognition and Old Age Psychiatry Clinic, Gothenburg, Sweden; Section Genomics of Neurodegenerative Diseases and Aging (J.N.), Department of Clinical Genetics, Vrije Universiteit Amsterdam, Amsterdam UMC, the Netherlands; Institute of Social Medicine (S.G.R.-H., S.R., A.P.), Occupational Health and Public Health (ISAP), Medical Faculty, University of Leipzig, Germany; School of Psychology (S.R.), Massey University, Albany Campus, Auckland, New Zealand; Global Brain Health Institute (GBHI) (S.R.), Trinity College Dublin, Ireland; Department of Medicine and Psychiatry (A.L., C.D.-l-C.), Universidad de Zaragoza; Instituto de Investigación Sanitaria Aragón (IIS Aragón) (A.L., C.D.-l-C., E.L.), Zaragoza; CIBERSAM (A.L., C.D.-l-C., E.L.), Madrid, Spain; Department of Preventive Medicine and Public Health (E.L.), Universidad de Zaragoza, Spain; Department of Neurology (R.B.L., M.J.K., C.A.D.), and Department of Epidemiology and Population Health (R.B.L., C.A.D.), Albert Einstein College of Medicine, Bronx, NY; Department of Neuropsychiatry (K.W.K., J.W.H.), Seoul National University Bundang Hospital, Seongnam; Department of Psychiatry (K.W.K., J.W.H.), Seoul National University College of Medicine; Department of Brain and Cognitive Sciences (K.W.K.), Seoul National University College of Natural Sciences; Workplace Mental Health Institute (D.J.O.), Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea; Golgi Cenci Foundation (E.R., A.D., M.R.), Abbiategrasso, Milan; Department of Brain and Behavioural Sciences (E.R.), University of Pavia, Italy; 1st Department of Neurology (N.S.), Aiginition Hospital, National and Kapodistrian University of Athens, Greece; Department of Neurology (N.S.), Columbia University, New York, NY; School of Health Sciences and Education (M.Y.), Department of Nutrition and Dietetics, Harokopio University; Department of Neurology (T.D.), University Hospital of Larissa; Faculty of Medicine (T.D.), School of Health Sciences, University of Thessaly, Larissa, Greece; Department of Psychiatry (H.C.H.), Indiana University School of Medicine; Indiana Alzheimer Disease Research Center (H.C.H., S.G.), Indiana Alzheimer Disease Research Center; Department of Biostatistics and Health Data Science (S.G.), Indiana University School of Medicine, Indianapolis; Institut for Neurosciences of Montpellier INM (I.C., K.R.), University Montpellier, INSERM; Institut du Cerveau Trocadéro (K.R.), Paris, France; School of Psychology (K.J.A.), and Ageing Futures Institute (K.J.A.), University of New South Wales; Neuroscience Research Australia (K.J.A.), Sydney; National Centre for Epidemiology and Population Health (N.C.), Australian National University, Canberra, Australia; Department of Geriatric Psychiatry (S.X., L.Y., W.L.), Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine; Alzheimer's Disease and Related Disorders Center (S.X., L.Y., W.L.), Shanghai Jiao Tong University, China; Inserm U1094 (M.G., P.-M.P., V.A.), IRD UMR270, Univ. Limoges, CHU Limoges, EpiMaCT-Epidemiology of Chronic Diseases in Tropical Zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, France; Laboratory of Chronic and Neurological Diseases Epidemiology (LEMACEN) (M.G.), Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin; Department of Cardiology (V.A.), Dupuytren 2 University Hospital, Limoges, France; School of Medicine (M.N.H.), University of California, San Francisco; Robert N. Butler Columbia Aging Center (A.A.), Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; Departamento de Psiquiatria (M.S.), Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Brazil; and Neuropsychiatric Institute (P.S.S.), Prince of Wales Hospital, Sydney, Australia.
Article Synopsis
- Previous studies suggest that using antihypertensive medication in older adults may lower the overall risk of dementia, but the effects on different types of dementia, particularly Alzheimer’s disease (AD), are still uncertain.
- This research analyzed data from over 31,000 participants across multiple countries, focusing on how history of hypertension and blood pressure levels impact the risk of developing AD and non-AD types of dementia.
- The findings indicated that untreated hypertension significantly increases the risk of developing AD and non-AD dementia compared to healthy individuals, while treated hypertension showed a similar risk for non-AD but not a significant difference between treated and untreated groups.
Pioneering Metal-Free Late-Stage C-H Functionalization Using Acridinium Salt Photocatalysis.
Chemistry
December 2024
Università degli Studi di Cagliari, Dipartimento di Scienze Chimiche e Geologiche, Cittadella Universitaria, 09042, Cagliari, Italy.
Using organic dyes as photocatalysts is an innovative approach to photocatalytic organic transformations. These dyes offer advantages such as widespread availability, adaptable absorption properties, and diverse chemical structures. Recent progress has led to the development of organic photocatalysts that can utilize visible light to modify chemically inert C-H bonds.
View Article and Find Full Text PDFSignificantly enhanced critical current density and pinning force in nanostructured, (RE)BCO-based, coated conductor.
Nat Commun
August 2024
Laboratorio "LAMBDA"-Dipartimento di Fisica, Università di Salerno and CNR-SPIN Unità di Salerno, Fisciano (SA), Italy.
High-temperature superconducting wires have many large-scale, niche applications such as commercial nuclear fusion as well as numerous other large-scale applications in the electric power industry and in the defense, medical and transportation industries. However, the price/performance metric of these coated conductor wires is not yet favorable to enable and realize most large-scale applications. Here we report on probing the limits of J (H, T) possible via defect engineering in heteroepitaxially deposited high-temperature superconducting thin-films on coated conductor substrates used for long-length wire fabrication.
View Article and Find Full Text PDFAssessment of Thrombectomy versus Combined Thrombolysis and Thrombectomy in Patients with Acute Ischemic Stroke and Medium Vessel Occlusion.
Radiology
August 2024
From the Neuroendovascular Program, Massachusetts General Hospital & Brigham and Women's Hospital, Harvard University, Boston, Mass (A.A.D., R.W.R., C.J.S., J.D.R., A.B.P.); Departments of Medical Imaging and Neurosurgery, Neurovascular Centre, St. Michael's Hospital, Toronto, ON, Canada M5B 1W8 (A.A.D., N.M.C., T.R.M., V.M.P.); Departments of Neurologic Surgery & Radiology, Mayo Clinic, Rochester, Minn (S.G., H.K., R.K.); Cooper Neurologic Institute, Cooper University Hospital, Cooper Medical School of Rowen University, Camden, NJ (J.E.S., H.S., J.K., A.J.T., A.G.); Departments of Radiology & Neurology, Boston Medical Center, Boston, Mass (M.A., P. Klein, T.N.N.); Department of Interventional Neuroradiology, Stanford Medical Center, Palo Alto, Calif (J.J.H.); Department of Neurosurgery, Thomas Jefferson University, Philadelphia, Pa (K.E.N., A.A., S.I.T., P.J.); Department of Neurosurgery and Interventional Neuroradiology, Louisiana State University, Shreveport, La (H.A.S., B.M., N.A., H.H.C.S.); Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany (L.M., J.F. T.D.F.); Department of Neurology, Hôpital Civil Marie Curie, Charleroi, Belgium (A.D., F.B.); Department of Neuroradiology, University Hospital of Limoges, Université de Limoges, Limoges, France (G.F., A.R., S. Saleme, C.M.); Department of Radiology, Division of Neurointerventional Radiology, University of Massachusetts Medical Center, Worcester, Mass (A.L.K., A.S.P.); Department of Neuroradiology, Sana Kliniken, Lübeck GmbH, Lübeck, Germany (C.D.); Department of Neurosurgery, University of Texas Medical Branch, Galveston, Tex (P.T.K., M.C.); Department of Interventional Neuroradiology, Bordeaux University Hospital, Bordeaux, France (G.M., J.B., X.B.); Department of Neurology, Bordeaux University Hospital, Bordeaux, France (I.S.); Department of Neurology, University of Massachusetts Chan Medical School, Worcester, Mass (S.N., N.H.); Department of Psychiatry, University of Massachusetts Chan Medical School, Worcester, Mass (N.H.); Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass (N.H.); Department of Neurosurgery, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan (T.O., S.D.); Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore (L.L.L.Y., B.Y.Q.T.); Department of Medicine, Division of Neurology, National University Hospital, Singapore (B.Y.Q.T.); Department of Neurology, UTHealth McGovern Medical School, Houston, Tex (J.C.M.G., S.S.M.); Interventistica Neurovascolare, Ospedale Careggi di Firenze, Florence, Italy (S. Sheth, L.R., C.C.); Department of Neurologic Surgery, Division of Stroke and Endovascular Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, Calif (A.M.); Department of Endovascular Neurosurgery and Neuroradiology, Rutgers University New Jersey Medical School in Newark, Newark, NJ (P. Khandelwal); Department of Neurosurgery, Westchester Medical Center at New York Medical College, Valhalla, NY (A.B.); Department of Neuroradiology, Pitié-Salpêtrière Hospital, GRC BioFast, Sorbonne University, Paris, France (F.C., M.E., K.P.); Neurology Department, Faculty of Medicine, Tanta University, Egypt (M.E.); UOSA Neuroradiologia Interventistica, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy (I.V., A.P., A.M.A.); Department of Diagnostic and Interventional Neuroradiology, Centro Hospitalar Universitário do Porto, Porto, Portugal (J.P.F.); Department of Neurology, Centro Hospitalar Universitário do Porto, Porto, Portugal (R.V.); Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, Calif (M.Q.C., N.R.G.); Department of Vascular and Interventional Neuroradiology, Universitätsklinikum Heidelberg, Heidelberg, Germany (M.A.M., J.J., C.W.); Department of Neuroradiology, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France (V.C., R.A.R.); Department of Neurology, Gui de Chauliac Hospital, Montpellier University Medical Center, Montpellier, France (A.t.S.); Department of Radiology, Division of Neuroradiology, Johns Hopkins Medical Center, Baltimore, Md (V.Y.); Department of Neurology, University of Cincinnati Medical Center, Cincinnati, Ohio (P.H., L.M.C., Y.A.); Department of Interventional Neuroradiology, Nancy University Hospital, Nancy, France (B.G.); INSERM U1254, IADI, Université de Lorraine, Nancy, France (B.G.); Department of Radiology, Section of Interventional Neuroradiology, University Medical Center Münster, Münster, Germany (C.P.S.); Departments of Neurology & Neurosurgery, Christian Doppler Clinic, Paracelsus Medical University, Salzburg, Austria (C.H., M.K.O., C.J.G.); Department of Neurology, Sin-Lau Hospital, Tainan, Taiwan (C.Y.H.); UCLA Stroke Center and Department of Neurology Department, University of California Los Angeles, Los Angeles, Calif (D.S.L.); Department of Medicine, Division of Neurology, The Ottawa Hospital, Ottawa Hospital Research Institute and University of Ottawa, Ottawa, Ontario, Canada (I.T., R.F.); Department of Diagnostic and Interventional Neuroradiology, Erasme University Hospital, Brussels, Belgium (B.L.).
Article Synopsis
- * Data from 670 patients revealed that while IVT may improve some outcomes, such as higher chances of achieving a modified Rankin Scale score of 0-2 in univariable analysis, this benefit was not consistently observed in more rigorous multivariable analyses.
- * Overall, the findings suggest that adjunctive IVT may not significantly enhance clinical outcomes or safety compared to MT alone for this patient population.
Huntington's disease cellular phenotypes are rescued non-cell autonomously by healthy cells in mosaic telencephalic organoids.
Nat Commun
August 2024
Laboratory of Stem Cell Biology and Pharmacology of Neurodegenerative Diseases, Department of Biosciences, University of Milan, 20122, Milan, Italy.
Article Synopsis
- Huntington's disease (HD) leads to the degeneration of specific brain neurons, resulting in a mix of functional and dysfunctional cells, but the interactions between these cell types are not well understood.
- Researchers created brain organoids containing both healthy and HD cells, finding that HD organoids displayed neurodevelopmental issues and fewer GABAergic neurons compared to healthy ones.
- Healthy cells in mixed organoids helped to restore the identity and function of HD cells through direct interactions, suggesting that enhancing communication between different cell types could offer new treatment strategies for HD.
Clinical findings and outcome in feline tetanus: a multicentric retrospective study of 27 cases and review of the literature.
Front Vet Sci
July 2024
C.H.V. des Cordeliers, IVC Evidensia France, Meaux, France.
Tetanus is a toxigenic illness caused by the action of neurotoxin (TeNT), which results in partial or generalized muscle stiffness in infected mammals and birds. The disease is rarely reported in cats due to their innate resistance to the toxin. This multicentric retrospective study aimed to describe a significant population of cats with a diagnosis of tetanus and report their signalment, clinical and neurological signs, diagnostic findings, treatment, and outcome.
View Article and Find Full Text PDFExploring the Growth Dynamics of Size-Selected Carbon Atomic Wires with In Situ UV Resonance Raman Spectroscopy.
Small
December 2024
Department of Energy, Micro and Nanostructured Materials Laboratory - NanoLab, Politecnico di Milano, Via Ponzio 34/3, Milano, 20133, Italy.
Short carbon atomic wires, the prototypes of the lacking carbon allotrope carbyne, represent the fundamental 1D system and the first stage in carbon nanostructure growth, which still exhibits many open points regarding their growth and stability. An in situ UV resonance Raman approach is introduced for real-time monitoring of the growth of carbon atomic wires during pulsed laser ablation in liquid without perturbing the synthesis environment. Single-chain species' growth dynamics are tracked, achieving size selectivity by exploiting the peculiar optoelectronic properties of carbon wires and the tunability of synchrotron radiation.
View Article and Find Full Text PDFHearing Loss and Oxidative Stress: A Comprehensive Review.
Antioxidants (Basel)
July 2024
ASP Ragusa-Hospital Giovanni Paolo II, 97100 Ragusa, Italy.
Article Synopsis
- Hearing loss is commonly linked to oxidative stress, suggesting that reactive oxygen species (ROS) damage the cochlea and contribute to various types of hearing loss, including age-related and noise-induced impairment.
- Antioxidant therapies have shown promise in reducing hearing loss in studies, while new treatment methods like gene therapy and targeted drug delivery may offer innovative solutions for managing oxidative stress in the auditory system.
- This review aims to deepen understanding of the relationship between oxidative stress and hearing loss, highlighting the need for more personalized treatment strategies and setting a foundation for future research.
Transition Metal-Driven Selectivity in Direct C-H Arylation of Imidazo[2,1-b]Thiazole.
ChemistryOpen
November 2024
Dipartimento di Chimica e Chimica Industriale, Università di Pisa, Via Giuseppe Moruzzi, 13, 56124, Pisa, Italy.
A selective direct arylation of the different Csp2-H bonds of imidazo[2,1-b]thiazole with (hetero) aryl halides can be achieved simply by switching from a palladium catalyst system to the use of stoichiometric amounts of copper. The observed selectivity, also rationalized by DFT calculations, can be explained by a change in the mechanistic pathways between electrophilic palladation and base-promoted C-H metalation.
View Article and Find Full Text PDFExpanding the Mutational Landscape and Clinical Phenotype of CHD2-Related Encephalopathy.
Neurol Genet
August 2024
From the Department of Neuromuscular Disorders (A.C.-H., T.L., B.A., R.K., R.M., S.E., H.H.); Department of Clinical and Experimental Epilepsy (A.C.-H.), UCL Queen Square Institute of Neurology; The Francis Crick Institute (A.C.-H.), London, United Kingdom; Cyprus Paediatric Neurology Institute (S.S., P.N.), Nicosia, Cyprus; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (M. Scala, P.S.), Università Degli Studi di Genova; U.O.C. Genetica Medica (M. Scala, F.Z.), IRCCS Istituto Giannina Gaslini, Genoa, Italy; Department of Neurosciences, Pediatric Psychiatry and Neurology (P.B.), Santobono-Pausilipon Children's Hospital, Naples, Italy; Medical Genetics Unit (F.M.), IRCCS Istituto Giannina Gaslini, Genoa, Italy; Department of Paediatric Neurology (S.B.), Tbilisi State Medical University, GA; Department of Pediatric Neurology (V.M.S., V.G.), Indira Gandhi Institute of Child Health, Bangalore, India; MediClub Hospital (U.G.), Baku, Azerbaijan; Department of Clinical and Functional Neurology (A.M., A.-L.P., C.B., D.M.V.), University Hospital of Lyon, Pierre-Bénite, France; Division of Pediatric Neurology (A.G., H.P.), Department of Pediatrics, Faculty of Medicine, Erciyes University, Kayseri, Turkey; Department of Paediatric Clinical Epileptology, Sleep Disorders and Functional Neurology (J. de Bellescize), University Hospitals of Lyon; Pediatric and Fetal Imaging Department (S.C.), Femme-Mere-Enfant Hospital, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, France; Department of Neuropediatrics (A.W.), Jena University Hospital, Jena, Germany; MVZ Mitteldeutscher Praxisverbund Humangenetik GmbH (A.S.), Johannesstr. 147, Erfurt, Germany; Pediatric Neurology Unit (A.R.-P.), Pediatrics Department, Hospital Universitari Germans Trias I Pujol, Universitat Autonoma de Barcelona, Spain; Department of Genetics (N.C., G.L.), Hospices Civils de Lyon, France; NeuroMyoGene Institute (N.C., G.L.), CNRS UMR 5261-INSERM U1315, Claude Bernard Lyon 1 University, France; Hunter Genetics (H.G.), Waratah, NSW 2298, Australia; University of Newcastle, Callaghan, NSW 2308, Australia; John Hunter Children's Hospital (J. Brown), Australia; Institute of Medical Genetics (T.F., K.S., A.R.), University of Zurich, Zurich, Switzerland; (A.R.), University Children's Hospital Zurich; University of Zurich Research Priority Program ITINERARE: Innovative Therapies in Rare Diseases, AdaBD: Adaptive Brain Circuits in Development and Learning, Switzerland; Neuroradiology Unit (M. Severino.), IRCCS Giannina Gaslini Institute, Genoa, Italy; University of Nicosia Medical School (P.N.), Nicosia, Cyprus.
Objectives: To present a case series of novel variants in patients presenting with genetic epileptic and developmental encephalopathy.
Background: CHD2 gene encodes an ATP-dependent enzyme, chromodomain helicase DNA-binding protein 2, involved in chromatin remodeling. Pathogenic variants in CHD2 are linked to early-onset conditions such as developmental and epileptic encephalopathy, drug-resistant epilepsies, and neurodevelopmental disorders.
Impact of Cytochrome P450 Enzyme on Fruit Quality.
Int J Mol Sci
June 2024
Department of Agricultural, Forestry and Food Sciences, University of Turin, Largo Paolo Braccini 2, 10095 Grugliasco, TO, Italy.
Cytochrome P450 enzymes are monooxygenases widely diffused in nature ranging from viruses to man. They can catalyze a very wide range of reactions, including the ketonization of C-H bonds, N/O/S-dealkylation, C-C bond cleavage, N/S-oxidation, hydroxylation, and the epoxidation of C=C bonds. Their versatility makes them valuable across various fields such as medicine, chemistry, and food processing.
View Article and Find Full Text PDFBoth Hamstring and Quadriceps Tendon Autografts Offer Similar Functional Outcomes After Arthroscopic Anterior Cruciate Ligament Reconstruction in Patients Aged 50 Years or Older.
Arthroscopy
July 2024
Gelenkpunkt-Sports and Joint Surgery, FIFA Medical Center of Excellence, Innsbruck, Austria; Research Unit for Orthopedic Sports Medicine and Injury Prevention (OSMI), Private University for Health Sciences, Medical Informatics and Technology, Innsbruck, Austria. Electronic address:
Purpose: To compare the outcomes of hamstring tendon (HT) and quadriceps tendon (QT) autografts for anterior cruciate ligament (ACL) reconstruction in patients aged 50 years or older in terms of patient-reported functional outcomes, graft failure rates, complications, return to sports activity, and sports preference.
Methods: Between 2010 and 2022, prospectively collected data were obtained from an institutional database. Patients aged 50 years or older who underwent primary arthroscopic ACL reconstruction with either HT or QT autograft and had a minimum 2-year follow-up were included.
Mechanism of non-phenolic substrate oxidation by the fungal laccase Type 1 copper site from : the case of benzo[]pyrene and anthracene.
Dalton Trans
July 2024
Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy.
Laccases (EC 1.10.3.
View Article and Find Full Text PDFAssociation of Body Mass Index and Parkinson Disease: A Bidirectional Mendelian Randomization Study.
Neurology
August 2024
From the Université Paris-Saclay (C.D., P.-E.S., B.P., A.E.), UVSQ, Inserm, Gustave Roussy, CESP, Villejuif, France; Centre for Genetic Epidemiology (A.A.K.S., M.S.), Institute for Clinical Epidemiology and Applied Biometry, and Department for Neurodegenerative Diseases (C.S., K.B., T.G.), Hertie Institute for Clinical Brain Research, University of Tubingen; German Center for Neurodegenerative Diseases (DZNE) (C.S., K.B., T.G.), Tubingen; Center for Human Genetics (S.G.), Universitatsklinikum Giessen und Marburg, Germany; Department of Public Health (P.-C.L.), National Cheng Kung University, Tainan, Taiwan; Translational Neuroscience (P.M., D.B., R.K.), Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-Belval; Institute of Human Genetics (M.R.B., P.L.), Helmholtz Zentrum München, Neuherberg, Germany; Molecular Genetics Section (A.B.S., D.H., C.E.), Laboratory of Neurogenetics, and Center for Alzheimer's and Related Dementias (A.B.S.), NIA, NIH, Bethesda, MD; Griffith Institute for Drug Discovery (G.D.M.), Griffith University, Nathan, Australia; Department of Neurology (A.A.Z.), Medical University of Vienna; Department of Neurology (W.P.), Wilhelminenspital, Austria; Tanz Centre for Research in Neurodegenerative Diseases (E.A.R., A.E.L.), University of Toronto; Edmond J. Safra Program in Parkinson's Disease (A.E.L.), Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN; Division of Neurology (A.E.L.), University of Toronto; Krembil Brain Institute (A.E.L.), Toronto, Ontario, Canada; Centre for Molecular Medicine and Innovative Therapeutics (S.K.), Murdoch University; Perron Institute for Neurological and Translational Science (S.K.), Nedlands, Australia; Department of Neurology and Neurosurgery (P.T.), University of Tartu; Neurology Clinic (P.T.), Tartu University Hospital, Estonia; Department of Neurologie (S.L., A.B., J.-C.C.), Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, Assistance Publique Hôpitaux de Paris, Sorbonne Université; Assistance Publique Hôpitaux de Paris (J.-C.C.), Department of Neurology, CIC Neurosciences; Univ. Lille (M.-C.C.-H., E.M.), Inserm, CHU Lille, UMR-S 1172-LilNCog-Centre de Recherche Lille Neurosciences & Cognition, France; Department of Neurology (A.B.D.), Ludwig Maximilians University of Munich; Department of Neurology (A.B.D.), Max Planck Institute of Psychiatry, Munich, Germany; Department of Neurology and Department of Clinical Genomics (A.B.D.), Mayo Clinic Florida, Jacksonville; Department of Neurology (G.M.H., E.D.), Laboratory of Neurogenetics, University of Thessaly, University Hospital of Larissa, Greece; Department of Neurology (G.M.H.), Medical School, University of Cyprus, Nicosia; 1st Department of Neurology (L. Stefanis, A.M.S.), Eginition Hospital, Medical School, National and Kapodistrian University of Athens; Center of Clinical Research, Experimental Surgery and Translational Research (L. Stefanis), Biomedical Research Foundation of the Academy of Athens, Greece; Department of Molecular Medicine (E.M.V.), University of Pavia; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Mondino Foundation (E.M.V.), Pavia; UOC Medical Genetics and Advanced Cell Diagnostics (S.P.), S. Andrea University Hospital, Rome; Department of Clinical and Molecular Medicine (S.P.), University of Rome; Department of Biomedical Sciences (L. Straniero), Humanitas University, Milan; Parkinson Institute (A.L.Z.), Azienda Socio Sanitaria Territoriale (ASST) Gaetano Pini/CTO, Milano; Parkinson Institute (G.P.), Fontazione Grigioni-Via Zuretti, Milan; Department of Neurology (L.B., C.F.), San Gerardo Hospital, Monza; Department of Medicine and Surgery and Milan Center for Neuroscience (L.B., C.F.), University of Milano Bicocca, Milano; Institute for Biomedical Research and Innovation (G.A.), National Research Council, Cosenza; Institute of Neurology (A.Q.), Magna Graecia University; Institute of Molecular Bioimaging and Physiology National Research Council (M.G.), Catanzaro, Italy; Department of Integrative Physiology and Bio-Nano Medicine (H.M., A.N.), National Defense Medical College, Saitama; Department of Neurology (N.H., K.N.), Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan; Department of Neurology (S.J.C.), Asan Medical Center, University of Ulsan College of Medicine; Department of Neurology (Y.J.K.), Yonsei University College of Medicine, Seoul, South Korea; Neurology (P.K., R.K.), Centre Hospitalier de Luxembourg; Department of Neurology (B.P.C.V.D.W., B.R.B.), Donders Institute for Brain, Cognition and Behaviour, Nijmegen, Radboud University Medical Centre, the Netherlands; Department of Neurology (M.T., L.P.), Oslo University Hospital, Norway; Instituto de Medicina Molecular João Lobo Antunes (L.C.G., J.J.F.), Faculdade de Medicina, Universidade de Lisboa; Department of Neurosciences and Mental Health (L.C.G.), Neurology, Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte (CHULN); Laboratory of Clinical Pharmacology and Therapeutics (J.J.F.), Faculdade de Medicina, Universidade de Lisboa, Portugal; Division of Molecular Biology and Human Genetics (S.B.), Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Division of Neurology (J.C.), Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa; Parkinson's disease & Movement Disorders Unit (E.T.), Neurology Service, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona; Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED: CB06/05/0018-ISCIII) (E.T.); Lab of Parkinson Disease and Other Neurodegenerative Movement Disorders (M.E.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Institut de Neurociències, Universitat de Barcelona; Fundació per la Recerca Biomèdica i Social Mútua Terrassa (P.P., M.D.-F.), Terrassa; Movement Disorders Unit (P.P., M.D.-F.), Department of Neurology, Hospital Universitari Mutua de Terrassa, Barcelona, Spain; Department of Clinical Neuroscience (K.W.), Department of Medical Epidemiology and Biostatistics (K.W., N.L.P.), and Department of Neuroscience (C.R., A.C.B.), Karolinska Institutet, Stockholm; Department of Clinical Sciences Lund (A.P., C.H.), Neurology, Skåne University Hospital, Lund University, Sweden; University of Birmingham and Sandwell and West Birmingham Hospitals NHS Trust (C.E.C.); Faculty of Medicine (K.E.M.), Health and Life Sciences, Queens University, Belfast; Department of Clinical and Movement Neurosciences (M.M.T.), UCL Queen Square Institute of Neurology, University College London, United Kingdom; Department of Neurology (D.K., L.F.B.), Northwestern University Feinberg School of Medicine, Chicago, IL; Metabolic Biochemistry (L.F.B.), Biomedical Center (BMC), Faculty of Medicine, Ludwig-Maximilians-Universität München; Munich Cluster for Systems Neurology (SyNergy) (L.F.B.); German Center for Neurodegenerative Diseases (DZNE) (L.F.B.), Munich, Germany; Department of Neurology (M.F.), McKnight Brain Institute, University of Florida, Gainesville; Parkinson's Research Clinic (R.K.), Centre Hospitalier de Luxembourg; and Transversal Translational Medicine (R.K.), Luxembourg Institute of Health (LIH), Strassen.
Article Synopsis
- The study investigates the relationship between body mass index (BMI) and Parkinson's disease (PD) using a method called Mendelian randomization to determine if higher genetically predicted BMI is linked to a lower incidence of PD.
- Researchers analyzed genetic data from large groups of individuals, including over 800,000 for BMI and nearly 29,000 for PD, focusing on factors like age, disease duration, and gender to examine the associations.
- Results indicated an inverse relationship between genetically predicted BMI and PD, particularly among younger participants and women, suggesting that lower BMI may be associated with a higher risk of developing Parkinson's disease.
Amivantamab plus Lazertinib in Previously Untreated -Mutated Advanced NSCLC.
N Engl J Med
October 2024
From the Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine (B.C.C.), Samsung Medical Center, Sungkyunkwan University School of Medicine (S.-H.L.), and the Lung Cancer Center, Asan Medical Center Cancer Institute (S.-W.K.), Seoul, the Department of Hematology-Oncology, Seoul National University Bundang Hospital, Seongnam (J.-S.L.), and the Medical Department, Chungbuk National University Hospital, Cheongju (K.-H.L.) - all in South Korea; the Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai (S.L.), Harbin Medical University Cancer Hospital, Harbin (B.L.), the Department of Medical Oncology, Huizhou Municipal Central Hospital of Guangdong Province, Huizhou (H.X.), and Jilin Cancer Hospital, Changchun (Y.C.) - all in China; the Medical Oncology Service, Vall d'Hebron Barcelona Hospital Campus-Vall d'Hebron University Hospital, Barcelona (E. Felip), and the Medical Oncology Department, Hospital Regional Universitario de Málaga y Virgen de la Victoria, Institute of Biomedical Research of Malaga, Malaga (V.G.C.) - both in Spain; Virginia Cancer Specialists, Fairfax (A.I.S.); Institut Curie, Institut du Thorax Curie-Montsouris, Paris (N.G.), and Paris-Saclay University, Université de Versailles Saint-Quentin-en-Yvelines, Versailles (N.G.), and Paris-Saclay University and Institut Gustave Roussy, Villejuif (B.B.) - all in France; the National Cancer Institute, Kyiv, Ukraine (Y.O.); the Division of Medical Oncology, Department of Medicine, Siriraj Hospital Faculty of Medicine, Mahidol University Bangkok Noi Campus, Bangkok, Thailand (P.D.); the Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur (A.A.), and the Department of Internal Medicine, Division of Respiratory Medicine, International Islamic University Malaysia Medical Specialist Center, Pahang (S.-H.H.) - both in Malaysia; British Hospital of Buenos Aires, Central British Hospital, Buenos Aires (E.K.); the Department of Medical Oncology, Barretos Cancer Hospital, São Paulo (J.M.D.); the School of Medicine and Institute of Medicine, Chung Shan Medical University, and the Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung (G.-C.C.), and the Department of Medical Oncology, National Taiwan University Cancer Center, Taipei (J.C.-H.Y.) - both in Taiwan; the Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata (H.Y.), and the Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka (H.H.) - both in Japan; the Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital, and the National Center for Tumor Diseases Heidelberg, German Center for Lung Research, Heidelberg, Germany (M.T.); City of Hope National Medical Center, Duarte (D.N.), Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (S.-H.I.O.), and Janssen Research and Development, San Diego (E. Fennema, D.M., S.M.S.) - all in California; St. John of God Murdoch Hospital, Murdoch, WA, Australia (S.M.); the Department of Medical Oncology, Division of Adult Solid Tumor, Tata Memorial Center and Homi Bhabha National Institute, Mumbai, India (K.P.); the Local Health Unit Authority of Romagna, Ravenna Hospital and Department of Onco-Hematology, Santa Maria delle Croci Hospital of Ravenna, Ravenna (M. D'Arcangelo), and the Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan (F.M., A.P.) - both in Italy; Health Pharma Professional Research, Mexico City (J.A.-A.), Oncología Médica, Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde," Guadalajara, and Universidad de Guadalajara, Guadalajara (J.C.V.L.) - all in Mexico; Instituto Português de Oncologia do Porto, Porto, Portugal (S.A.); Moscow City Oncology Hospital No. 62 (D.S.) and the Medical Center in Kolomenskoe (M.P.) - both in Moscow; the Department of Medical Oncology, Ankara Bilkent City Hospital and Ankara Yıldırım Beyazıt University (M.A.N.Ş.), and the Department of Medical Oncology, Gazi University Faculty of Medicine (O.Y.) - both in Ankara, Turkey; the Department of Medical Oncology, Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom (R.C.); the Division of Hematology-Oncology, Henry Ford Cancer Institute, Henry Ford Health, Detroit (S.M.G.); Janssen Research and Development, Raritan, NJ (J.X., T.S., M.M., M. Daksh, M.B.); Janssen Research and Development, Spring House, PA (M.E., R.I., P.L., S. Shah, J.M.B., S. Sethi, R.E.K.); and Johnson and Johnson Clinical Innovation, Campus Basel, Allschwil, Switzerland (I.L.).
Article Synopsis
- - The study investigates the effectiveness of amivantamab plus lazertinib compared to osimertinib in treating patients with advanced non-small-cell lung cancer (NSCLC) caused by specific genetic mutations.
- - Results showed that patients receiving the amivantamab-lazertinib treatment had a significantly longer progression-free survival (23.7 months) than those on osimertinib (16.6 months), and the response rate was similar among both groups.
- - Side effects primarily related to treatment were noted, but the overall survival analysis indicated a potential benefit for amivantamab-lazertinib over osimertinib, with fewer serious complications leading to treatment discontinuation.
Prehospital tirofiban increases the rate of disrupted myocardial infarction in patients with ST-segment elevation myocardial infarction: insights from the On-TIME 2 trial.
Eur Heart J Acute Cardiovasc Care
August 2024
Department of Cardiology, Zuyderland Medical Center, Heerlen, Henri Dunantstraat 5, 6419 PC Heerlen, The Netherlands.
Article Synopsis
- In patients with STEMI, prehospital tirofiban showed promise in enhancing myocardial reperfusion, but its effect on disrupted myocardial infarction rates remains uncertain, especially with high-sensitivity cardiac troponin (hs-cTn) tests.!* -
- The On-TIME 2 trial demonstrated that prehospital tirofiban was associated with a higher incidence of disrupted MI, occurring in 8% of the tirofiban group versus 4% in the placebo group, and the results remained significant even after adjustments for other factors.!* -
- Importantly, none of the patients with disrupted MI died during a one-year follow-up, compared to a 2.6% mortality rate in patients without disrupted MI
Safe and efficient practice of parenteral nutrition in neonates and children aged 0-18 years - The role of licensed multi-chamber bags.
Clin Nutr
July 2024
University of Liège, Liège, Belgium. Electronic address:
Parenteral nutrition (PN) is recognized as a complex high-risk therapy. Its practice is highly variable and frequently suboptimal in pediatric patients. Optimizing care requires evidence, consensus-based guidelines, audits of practice, and standardized strategies.
View Article and Find Full Text PDFSafety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis.
Blood Adv
September 2024
Department of Oncology and Hematology-Oncology, University of Milano Statale, Milan, Italy.
Article Synopsis
- The ACE-536-MF-001 trial studied the effects of luspatercept on myelofibrosis patients, enrolling 95 participants divided into four groups based on their dependency on transfusions and anemia status.
- The primary outcome measured was the anemia response rate, where 14%-26% of patients met the criteria based on their cohort, with significant hemoglobin increases noted, particularly in non-transfusion dependent patients.
- Adverse events were common, with 94% of patients experiencing at least one; the most frequent were hypertension and other manageable issues, while the treatment showed consistent efficacy and safety results similar to previous studies.
Iridium-Catalyzed C-H Borylations: Regioselective Functionalizations of Calix[4]arene Macrocycles.
J Org Chem
June 2024
Dipartimento di Scienze Chimiche, della Vita e della Sostenibilità Ambientale, Università di Parma, Parco Area delle Scienze 17/A, 43124 Parma, Italy.
We report iridium-catalyzed C-H borylations for the regioselective synthesis of distally disubstituted calix[4]arene macrocycles. The atom- and step-economical method led to a broad family of calix[4]arenes in good yields and functional group tolerance. The synthetic utility of the C-H borylation protocol was finally illustrated with several late-stage modifications for the synthesis of elaborate calix[4]arenes frameworks, otherwise challenging to achieve with commonly employed procedures.
View Article and Find Full Text PDFExploring the healing power of stems: insights into extraction methods, polyphenolic composition, and health-promoting activities.
Int J Environ Health Res
May 2024
Laboratory of Bioresources Biotechnology, Ethnopharmacology and Health, Team: Microbiology, Faculty of Sciences, Mohammed First University, Oujda, Morocco.
This work aimed to evaluate the effect of different extraction solvents on the polyphenolic content, antioxidant and antibacterial activity of stems. The results obtained show that the extraction yield depends strongly on the polarity of the solvent and the extraction method. The ethanolic extract had the highest yield in both extraction methods investigated, namely Soxhlet ( = 9.
View Article and Find Full Text PDFREAL-Colon: A dataset for developing real-world AI applications in colonoscopy.
Sci Data
May 2024
Cosmo Intelligent Medical Devices, Dublin, Ireland.
Article Synopsis
- - Detection and diagnosis of colon polyps are crucial for preventing colorectal cancer, and AI technologies can improve colonoscopy effectiveness through computer-aided detection (CADe) and diagnosis (CADx) systems.
- - The REAL-Colon dataset offers a large collection of 2.7 million native video frames from real-world colonoscopy, featuring 350,000 expert-annotated bounding boxes, which provide a more realistic dataset compared to existing down-sampled images.
- - This dataset includes comprehensive patient and procedural data, promoting transparency and enabling researchers to develop and benchmark more accurate AI algorithms for improved colonoscopy outcomes.
Use of Raman spectroscopy and PCA for quality evaluation and out-of-specification identification in biopharmaceutical products.
Eur J Pharm Biopharm
July 2024
Dipartimento di Scienza Applicata e Tecnologia, Politecnico di Torino, Corso Duca degli Abruzzi 24, 10129 Torino, Italy. Electronic address:
Over the past three decades, there was a remarkable growth in the approval of antibody-based biopharmaceutical products. These molecules are notably susceptible to the stresses occurring during drug manufacturing, often leading to structural alterations. A key concern is thus the ability to detect and comprehend these alterations caused by processes, such as aggregation, fragmentation, oxidation levels, as well as the change in protein concentration throughout the process steps, potentially resulting in out-of-spec products.
View Article and Find Full Text PDFIron-Catalyzed C-H Alkylation/Ring Opening with Vinylbenzofurans Enabled by Triazoles.
Angew Chem Int Ed Engl
August 2024
Dipartimento di Scienze Chimiche della Vita e della Sostenibilità Ambientale, Università di Parma, Parco Area delle Scienze17/A, 43124, Parma, Italy.
We report an unprecedented iron-catalyzed C-H annulation using readily available 2-vinylbenzofurans as the reaction pattern. The redox-neutral strategy, based on cheap, non-toxic, and earth-abundant iron catalysts, exploits triazole assistance to promote a cascade C-H alkylation, benzofuran ring-opening and insertion into a Fe-N bond, to form highly functionalized isoquinolones. Detailed mechanistic studies supported by DFT calculations fully disclosed the manifold of the iron catalysis.
View Article and Find Full Text PDFComputer-Aided Diagnosis for Leaving Colorectal Polyps In Situ : A Systematic Review and Meta-analysis.
Ann Intern Med
July 2024
Ted Rogers Centre for Heart Research, University Health Network, Toronto, Ontario, Canada (F.F.).
Article Synopsis
- Computer-aided diagnosis (CADx) aims to improve the prediction of polyp histology during colonoscopy, potentially decreasing unnecessary removals of harmless polyps, though its overall benefits and risks remain uncertain.
- The study sought to evaluate the effectiveness of CADx for diagnosing small rectosigmoid polyps (≤5-mm) by comparing the accuracy of endoscopists' predictions with and without CADx assistance.
- Analysis of ten studies involving over 3,600 patients indicated that while CADx showed high sensitivity (87.3%) and specificity (88.9%) in identifying neoplastic polyps, there was no significant change in the rate of nonneoplastic polyps predicted to be avoided for removal when CADx
Artificial Intelligence for Real-Time Prediction of the Histology of Colorectal Polyps by General Endoscopists.
Ann Intern Med
July 2024
University of Kansas Medical Center, Kansas City, Kansas (D.B., S.H., M.J., S.K., J.L., E.M., M.P., S.S., A.R.).
Article Synopsis
- - The study aimed to analyze how general endoscopists' ability to predict the histologic features of small colorectal polyps improved when using a computer-aided diagnosis (CADx) system during real-life colonoscopies in the U.S.
- - Results showed that while both unassisted and CADx-assisted predictions had similar sensitivity (around 90%), the assisted group's specificity was significantly higher, allowing more polyps to be resected or left untreated.
- - Despite the benefits seen in a clinical setting, the study noted that the use of CADx might not yield the same results in other real-world scenarios.